Brief: Xilio Therapeutics Reports Preclinical Data Of XTX301 In Cancer Annual Meeting
12/11/2021 12:30
Nov 12 (Reuters) - Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS ANNOUNCES PRECLINICAL DATA
DEMONSTRATING
ANTI-TUMOR ACTIVITY AND TOLERABILITY OF XTX301, A
TUMOR-SELECTIVE IL-12, AT SOCIETY FOR IMMUNOTHERAPY IN CANCER
ANNUAL MEETING
Source text for Eikon: ID:nGNX8Qv2BS
Further company coverage: XLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla